|
| |
ShireFounded in 1986, Shire plc is a global specialty pharmaceutical company with revenues for the full year 2005 of $1,599.3 million and an operating income of $(354.1) million. The growth rates for revenues were 17% for 2005 over the prior year. The Shire Mission
Shire’s mission is to develop and market medicines that improve the quality of life for patients and their caregivers. We do so through the following commitments and actions:
A focus on meeting our commitments and obligations to all our stakeholders: patients, physicians, employees, shareholders and the communities in which we live and work.
Maintaining the highest professional and ethical standards.
Building value-added relationships with physicians.
Focusing resources and organizing our work around select therapeutic areas
Implementing effective processes for identifying compounds and optimizing our drug development activities to bring the best drugs to market
Galvanizing the entire company around growing our business and executing our strategy
Fostering a rewarding and enjoyable workplace for our employees
An underlying passion for our work
| Contact Details: |
| Hampshire International Business Park Chineham |
| Basingstoke |
| Hampshire |
| RG24 8EP |
| United kingdom |
| Tel: | 44 1256 894 000 |
| Fax: | 44 1256 894 708 |
| Email: | custserv@uk.shire.com |
| WWW: | www.shire.com/shire/
|
| |
Recent Publications by Shire: |  |
Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
OBJECTIVE: To evaluate the pharmacokinetics of lisdexamfetamine dimesylate... | 5th November, 2009
| Clinical Pharmacology, Shire Development Inc., Wayne, PA 19087, USA.
| Postgrad Med. 2009 Sep;121(5):11-9.
DOI Direct Link |
A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.
OBJECTIVE: To evaluate the pharmacokinetics of lisdexamfetamine dimesylate... | 29th September, 2009
| 1Global Medical Affairs Shire Pharmaceuticals, Basingstoke, UK.
| Nephrol Dial Transplant. 2009 Oct 5.
DOI Direct Link |
A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy.
Nonadherence to antipsychotic medications in serious, persistent mental... | 3rd September, 2009
| Dr. Lasser is with Shire Pharmaceuticals (Dr. Lasser was with Johnson &
| Psychiatry (Edgmont). 2009 Apr;6(4):22-7.
|
Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?
Lanthanum carbonate is a non-calcium phosphate binder used to control... | 21st July, 2009
| Shire Pharmaceutical Development Ltd., Hampshire International Business
| Toxicol Lett. 2009 Aug 10;188(3):223-9. Epub 2009 Apr 1.
DOI Direct Link |
A rapid, fluorescence-based assay for detecting antigenic modulation of the acetylcholine receptor on human cell lines.
BACKGROUND: Myasthenia gravis (MG) is an autoimmune disease affecting... | 21st July, 2009
| Department of Preclinical Discovery, Shire Human Genetic Therapies, 700
| Cytometry B Clin Cytom. 2009 May;76(3):206-12.
DOI Direct Link |
→View more Shire research publications. |
Press Releases on Shire:
|
 |
| Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease |
24th November, 2009 |
|
DUBLIN, November 24 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced that it has submitted a MAA to the
European Medicines Agency
|
| Reportlinker Adds Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities |
18th November, 2009 |
Reportlinker |
NEW YORK, Nov. 18 /PRNewswire/ --
Reportlinker.com announces that a new market research report is available in its catalogue.
Alzheimer's and Parkinson's Diseases - A Global Update of Market
|
| Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants |
16th November, 2009 |
Shire plc |
PHILADELPHIA, Nov. 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended
|
| Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII |
12th November, 2009 |
Shire plc |
PHILADELPHIA, Nov. 12 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional
|
| Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research |
11th November, 2009 |
Pharma Market Research Conference |
PARSIPPANY, N.J., Nov. 11 /PRNewswire/ -- Pharma market research thought leaders are discovering new ways to take advantage of the tremendous developments and opportunities in the pharmaceutical
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 21 individuals from Shire using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 424 times since April 2007, the link to the organisation's website has been followed 60 times Recent Search Terms used to find this page: UK SHIRE data administrator | UK SHIRE data administrator | shire hgt, employees, blog | apricitabine patent | . Search for more companies in Basingstoke Search for more companies in Hampshire This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Shire |
